HUP0301831A2 - Gepiron bioaktív metabolitjainak alkalmazása pszichológiai rendellenességek kezelésére - Google Patents

Gepiron bioaktív metabolitjainak alkalmazása pszichológiai rendellenességek kezelésére

Info

Publication number
HUP0301831A2
HUP0301831A2 HU0301831A HUP0301831A HUP0301831A2 HU P0301831 A2 HUP0301831 A2 HU P0301831A2 HU 0301831 A HU0301831 A HU 0301831A HU P0301831 A HUP0301831 A HU P0301831A HU P0301831 A2 HUP0301831 A2 HU P0301831A2
Authority
HU
Hungary
Prior art keywords
gepirone
treatment
psychological disorders
bioactive metabolites
metabolites
Prior art date
Application number
HU0301831A
Other languages
English (en)
Inventor
Louis F. Fabre
Stephen J. Kramer
Edward H. Ruediger
Joseph P. Yevich
Original Assignee
Fabre-Kramer Pharmaceuticals, Inc.
Edward H. Ruediger
Joseph P. Yevich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fabre-Kramer Pharmaceuticals, Inc., Edward H. Ruediger, Joseph P. Yevich filed Critical Fabre-Kramer Pharmaceuticals, Inc.
Publication of HUP0301831A2 publication Critical patent/HUP0301831A2/hu
Publication of HU228963B1 publication Critical patent/HU228963B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Abstract

A találmány tárgya bioaktív gepiron metabolitok, így 3-OH gepiron,3,5-dihidroxi-gepiron, vagy 5-OH gepiron alkalmazása depresszió vagyszorongás tüneteinek enyhítésére szolgáló, emlősöknek adagolhatógyógyszerkészítmények előállítására. Ó
HU0301831A 1999-12-20 2000-12-18 Use of bioactive metabolites of gepirone for the treatment of psychological disorders HU228963B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17268499P 1999-12-20 1999-12-20
US09/709,741 US6534507B1 (en) 1999-12-20 2000-11-13 Methods for treating psychological disorders using bioactive metabolites of gepirone
PCT/US2000/034131 WO2001045687A2 (en) 1999-12-20 2000-12-18 Use of bioactive metabolites of gepirone for the treatment of psychological disorders

Publications (2)

Publication Number Publication Date
HUP0301831A2 true HUP0301831A2 (hu) 2003-09-29
HU228963B1 HU228963B1 (en) 2013-07-29

Family

ID=26868346

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301831A HU228963B1 (en) 1999-12-20 2000-12-18 Use of bioactive metabolites of gepirone for the treatment of psychological disorders

Country Status (20)

Country Link
US (1) US6534507B1 (hu)
EP (1) EP1242061B1 (hu)
JP (1) JP4236407B2 (hu)
KR (1) KR100602976B1 (hu)
CN (1) CN1411375A (hu)
AT (1) ATE294572T1 (hu)
AU (1) AU776409B2 (hu)
CA (1) CA2395458C (hu)
CZ (1) CZ300429B6 (hu)
DE (1) DE60019968T2 (hu)
ES (1) ES2241683T3 (hu)
HU (1) HU228963B1 (hu)
IL (2) IL150222A0 (hu)
MX (1) MXPA02006146A (hu)
NO (1) NO323304B1 (hu)
NZ (1) NZ519554A (hu)
PL (1) PL200378B1 (hu)
PT (1) PT1242061E (hu)
RU (1) RU2282448C2 (hu)
WO (1) WO2001045687A2 (hu)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016347A1 (en) * 2000-08-22 2002-02-28 Akzo Nobel N.V. Active metabolite of gepirone
US20040002500A1 (en) * 2002-06-28 2004-01-01 Fabre Kramer Pharmaceutical, Inc. Methods for treating attention deficit disorder
US20040000689A1 (en) * 2002-06-28 2004-01-01 Erh-Kun Lai Dual-bit MONOS/SONOS memory structure with non-continuous floating gate
CA2495659A1 (en) 2002-08-12 2004-02-19 Bristol-Myers Squibb Company Process for hydroxyazapirones
US20050004105A1 (en) * 2003-01-29 2005-01-06 Emer Leahy Treatment for a attention-deficit hyperactivity disorder
US20050165233A1 (en) * 2003-11-18 2005-07-28 Mourad Hamedi Continuous process for producing hydroxyazapirones by oxidation
BRPI0419179A (pt) * 2004-11-05 2007-12-18 Fabre Kramer Pharmaceuticals I formulação de alta dosagem de liberação prolongada de gepirona
EA201071282A1 (ru) * 2008-05-08 2011-04-29 Фэйбр-Крэймер Фармасьютикалз, Инк. 3-гидроксигепирон для лечения синдрома дефицита внимания и половой дисфункции

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4423049A (en) 1981-12-28 1983-12-27 Mead Johnson & Company 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines
US4956368A (en) 1989-07-24 1990-09-11 Bristol-Myers Company Metabolites and prodrug formulations of 8-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-8-azaspiro[4.5]decane-7,9-dione
US5478572A (en) 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form

Also Published As

Publication number Publication date
NO20022954L (no) 2002-06-19
IL150222A0 (en) 2002-12-01
HU228963B1 (en) 2013-07-29
EP1242061A2 (en) 2002-09-25
ATE294572T1 (de) 2005-05-15
ES2241683T3 (es) 2005-11-01
RU2002119400A (ru) 2004-01-27
KR20020082470A (ko) 2002-10-31
AU776409B2 (en) 2004-09-09
NO323304B1 (no) 2007-03-05
KR100602976B1 (ko) 2006-07-20
JP2004500362A (ja) 2004-01-08
IL150222A (en) 2009-09-22
RU2282448C2 (ru) 2006-08-27
NZ519554A (en) 2005-01-28
MXPA02006146A (es) 2004-08-23
PL364936A1 (en) 2004-12-27
WO2001045687A2 (en) 2001-06-28
CZ300429B6 (cs) 2009-05-20
CZ20022137A3 (cs) 2003-03-12
US6534507B1 (en) 2003-03-18
AU2268701A (en) 2001-07-03
PL200378B1 (pl) 2008-12-31
PT1242061E (pt) 2005-09-30
JP4236407B2 (ja) 2009-03-11
DE60019968T2 (de) 2006-02-02
CN1411375A (zh) 2003-04-16
WO2001045687A3 (en) 2002-04-25
CA2395458A1 (en) 2001-06-28
EP1242061B1 (en) 2005-05-04
DE60019968D1 (de) 2005-06-09
NO20022954D0 (no) 2002-06-19
CA2395458C (en) 2009-05-12

Similar Documents

Publication Publication Date Title
MY127980A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
YU30004A (sh) Upotreba flibanserina u lečenju seksualnih poremećaja
SE9701398D0 (sv) Novel compounds
HUP0400689A2 (hu) ABCA-1 szint-emelő vegyületek
ES2192839T3 (es) Timosina beta 4 oxidada.
DK0713701T3 (da) 2-Brommelatonin til behandling af søvnforstyrrelser
MY135838A (en) Methods for the treatment of mental disorders
BR0115162A (pt) Tratamentos antitumorais eficazes
HUP0301831A2 (hu) Gepiron bioaktív metabolitjainak alkalmazása pszichológiai rendellenességek kezelésére
HK1055079A1 (en) Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders
ES2162520T3 (es) Medicamentos basados en hiperforina y/o extractos de hiperforina.
ATE223721T1 (de) Edelfosin zur behandlung von hirntumoren
ATE303819T1 (de) Verwendung von langem pentraxin ptx3 zur herstellung eines arzneimittels zur verhütung und heilung von autoimmunkrankheiten
EE200100689A (et) IL6RIL6 kimääri kasutamine ravimi valmistamiseks,mis on ette nähtud neuroloogiliste haiguste ravimiseks, ning farmatseutiline kompositsioon
MXPA02011533A (es) Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
NO990450L (no) Behandling av sinnslidelser
PE20030236A1 (es) Derivados de bencimidazol 1-aril-2-n,s- u o-sustituidos, obtencion de medicamentos y preparados farmaceuticos que contienen estos derivados
ES2188742T3 (es) Trapidil para uso en la terapia de cuadros patologicos influenciables por la inmunomodulacion.
ATE293445T1 (de) Herstellung reiner stereoisomere von tricyclo- (5.2.1.0(2.6) )-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel
HUP9701284A2 (hu) 2,3-Benzodiazepin-származékok felhasználása az endogén opioid rendszerrel összefüggő betegségek és állapotok kezelésére, és megelőzésére alkalmas gyógyászati készítmények előállítására
AR030945A1 (es) Amidas de acido fenilciclohexanocarboxilico sustituido y su uso
MD2053B1 (en) Remedy with interferon inducing action
HUP9701606A2 (hu) Szulbutiamin alkalmazása bizonyos pszichomotoros és pszichointellektuális rendellenességek kezelésére használható gyógyszerkészítmények előállítására
HUP0102116A2 (hu) Paroxetin-aszkorbát, eljárás az előállítására és gyógyászati alkalmazása
MD2491F1 (en) Use of bromide of S-ethyl isothiouronium (isoturone) for algodysmenorrhea treatment